Community Acquired or Acquiring Hospital Acquired PneumoniaPHENOMENONNCT06916481
Definition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures
An observational study of Community Acquired or Acquiring Hospital Acquired Pneumonia, run by Assistance Publique - Hôpitaux de Paris at 6 sites in France.
Trial summary
Background: Pneumonia remains a leading cause of antibiotic consumption globally, contributing significantly to the burden of antimicrobial resistance (AMR). The respiratory microbiome plays a crucial role in the emergence of AMR and therapeutic failure in both community-acquired pneumonia (CAP) and hospital-acquired… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Community Acquired or Acquiring Hospital Acquired Pneumonia
- How many people
- 300 participants
- Where
- 6 sitesFrance
- Study dates
- 6 Nov 2025to 15 Sep 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The population of interest is specific to each cohort. > For cohort 1: patients will be informed orally and in writing by the investigator on the delegation log during their hospitalization before inclusion. Patients will be informed of their right to decline participation and an informed written consent will be obtained by the investigator for biobank collection. > For cohorts 2 and 3: some patients may not be able to decline participation (sedated, ventilated). In these cases, relatives, if they are present, will be informed orally and in writing by the investigator on the delegation log. Relatives will be informed of their right to decline participation on behalf of the patient. Patients will be informed as soon as their health allows it. Patients will be informed of their right to decline to continue, and of their right to forbid the use of already collected data and/or samples.
Who may be able to join
- Cohort 1: CAP at emergency department and requiring hospitalization in general wards :
- Age ≥18 years
- Hospitalization in a medical department (not ICU)
- Presence of at least one acute clinical sign compatible with pneumonia (e.g. dyspnea, cough, purulent sputum or purulent tracheal aspirations or crackles), and temperature above 38°C in the 48 hours prior to inclusion
- AND new pulmonary infiltrate on chest X-ray or CT scan (on Day 0 or within three days of inclusion)
- Efficient treatment initiated for less than 24 hours
Show all 20Show fewer
- Sputum collection possible
- Cohort 2: Severe CAP with ICU hospitalization :
- Age ≥18 years
- Hospitalization in intensive care unit for at least 24 hours.
- Presence of at least one acute clinical sign compatible with pneumonia (e.g. dyspnoea, cough, purulent sputum or crackles), temperature greater than 38°C in the 48 hours prior to hospital admission
- AND new pulmonary infiltrate on chest X-ray or CT scan (on Day 0 or within three days of inclusion)
- Efficient treatment initiated for less than 24 hours
- Sputum collection or tracheal aspiration or any distal bacterial sample (BAL, plugged telescopic catheter) collection possible
- Cohort 3: vHAP or VAP :
- Age ≥18 years
- vHAP: mechanical ventilation, in a patient previously hospitalized for more than 48 hours at the onset of new or worsening radiological infiltrates and 2 of the following: fever or hypothermia, leukocytosis > 12 G/L or leukopenia < 4G/L, purulent tracheal aspirates,
- VAP: mechanical ventilation for more than 48 hours, new or worsening radiological infiltrates and 2 of the following: fever (>38°C) or hypothermia (<36.5°C) in the 24 hours prior to inclusion, leucocytosis> 12 G/L or leukopenia < 4G/L, purulent tracheal aspirates
- AND plugged telescopic catheter (PTC) ≥103colony-forming units (CFU)/ml or bronchoalveolar lavage (BAL) culture ≥104 CFU/ml or purulent tracheal aspirates ≥ 106 UFC/mL
- AND treated with active antibiotic therapy for pneumonia for less than 24 hours
Who cannot join
- Cohort 1: CAP with hospitalization in general wards :
- AIDS
- Patient on high-dose corticosteroids >2 mg/kg prednisone equivalent
- Bone marrow transplant patients
- Cancer patients undergoing chemotherapy within 3 months of inclusion
- Opposition of the patient (absence of informed written consent)
Show all 26Show fewer
- Scheduled transfer to another hospital
- Patient under guardianship or comparable legal status
- NB: Patients included in the cohort 1 and referred to ICU within the first 24 hours will be included in the cohort 2.
- Cohort 2: Severe CAP with ICU hospitalization :
- AIDS
- Patient on high-dose corticosteroids >2 mg/kg prednisone equivalent
- Bone marrow transplant patients
- Cancer patients undergoing chemotherapy within 3 months of inclusion
- Stays shorter than 24h in the ICU will be exlcuded
- Absence of informed written consent of the patient if they are fit, or absence of informed written consent of the relative/caregiver (for patients unable to understand the information and in the absence of a relative/caregiver, emergency inclusion is authorized)
- Decision to forego life-sustaining therapy
- Patient under guardianship or comparable legal status
- Cohort 3: vHAP or VAP :
- AIDS
- Patient on high-dose corticosteroids >2 mg/kg prednisone equivalent
- Bone marrow transplant patients
- Cancer patients undergoing chemotherapy within 3 months of inclusion
- Absence of informed written consent of the patient if he is fit, or absence of informed written consent of the relative (for patients unable to understand the information and in the absence of a relative, emergency inclusion is authorized)
- Decision to forego life-sustaining therapy
- Patient under guardianship or comparable legal status
Trial locations and contacts
6 sites in 1 country. Contact the study team or a site near you to ask about taking part.
6 sites in 1 country
France6 sites, 3 recruiting
- Active, not recruiting
Hospital Beaujon
Clichy
- Not yet recruiting
CHU Nantes - Saint Herblain
Nantes
Karim Lakhal, MD, karim.lakhal@chu-nantes.fr
- Not yet recruiting
CHU Nantes - Saint Herblain
Nantes
Bertrand Rozec, MD, PHD, bertrand.rozec@chu-nantes.fr
- Active, not recruiting
CHU Nantes
Nantes
- Recruiting
Hospital Bichat
Paris, 75 018
Jean-françois Timsit, MD, PHD, +33 1 40 25 77 07, jean-françois.timsit@aphp.fr
Antoine Roquilly, MD, PHD, Antoine.ROQUILLY@chu-nantes.fr
- Active, not recruiting
Hospital Bichat
Paris
About this study
Background: Pneumonia remains a leading cause of antibiotic consumption globally, contributing significantly to the burden of antimicrobial resistance (AMR). The respiratory microbiome plays a crucial role in the emergence of AMR and therapeutic failure in both community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). The PHENOMENON study aims to investigate the relationship between the respiratory microbiome composition and clinical outcomes to improve the prediction of treatment failure and AMR emergence.
Methods: This multicenter prospective cohort study will include 300 adult patients across three cohorts: CAP in general wards, severe CAP in intensive care units (ICU), and ventilator-associated HAP (vHAP/VAP). Patients will undergo oropharyngeal and rectal swabbing at admission (Day 0), Day 3, Day 7-10, and Day 90, along with blood sampling and endotracheal aspirates in intubated patients. The primary objective is to assess the association between baseline respiratory microbiome composition and time to antibiotic response within 7-10 days. The composite primary endpoint includes clinical failure, microbiological failure, or AMR emergence. Secondary endpoints explore the association between microbiome composition and pneumonia recurrence, severity, hospital length of stay, and mortality at Day 28 and Day 90.
Expected Outcomes: This study will provide insights into the predictive value of respiratory microbiome composition on antibiotic response and AMR emergence. Understanding these relationships may guide personalized antibiotic strategies and optimize pneumonia management, ultimately reducing treatment failure rates and improving patient outcomes.
Read the detailed description
Pneumonia can be acquired in the community such as COVID-19 or flu, or during hospitalization for a different medical condition.
The significant burden of CAP is set to increase with ageing populations and growing rates of comorbidity. CAP was the leading cause of communicable diseases and the second cause of disability-adjusted life-years loss in the world in 2019, even before the COVID-19 pandemic (GBD 2019 Adolescent Mortality Collaborators 2021; GBD 2019 Diseases and Injuries Collaborators 2020). CAP is classically induced by virulent bacteria (such as Streptococcus pneumoniae) or viruses (influenza), but also new pathogenic viruses such as SARS-CoV-2 (COVID-19).
Incidence of VAP ranges from 5% to 67% depending on case mix and diagnostic criteria. In the US, the incidence of VAP ranges from 2 to 16 episodes per 1,000 ventilator-day. The estimated risk of VAP is initially high and decreases to less than 0.5% per day after 14 days of mechanical ventilation. VAP increases the duration of hospitalization by 7 days and health-care costs by approximately $40,000 USD per episode (Safdar et al. 2005; Eber et al. 2010). Antimicrobial resistance is rising, leading to increased durations of hospital stay and excess deaths in septic patients worldwide. The World Health Organization considers antibiotic resistance to be one of the biggest global health threats we are currently facing. AMR, including malaria, tuberculosis and bacterial infections, may increase to 10 million fatalities worldwide by 2050. While some resistance is intrinsic in some bacterial taxa, the main issue is acquired resistance, as bacteria can exchange genetic material and thereby spread antibiotic resistance genes (ARG).
Previous carriage of extended-spectrum beta-lactamases-producing Enterobacterales (ESBL-E) is found in 5 to 25% of ICU patients. Although a previous carriage is the major risk factor associated with VAP related to ESBL-E, only 5% to 20% of the ESBL-E carriers will develop a VAP related to ESBL-E. Carriage status therefore has a high negative predictive value for ESBL-E-associated VAP, whereas positive predictive value, i.e., the probability of having an ESBL-E infection in case of ESBL-E carriage, is less than 50%.
When caring for patients with VAP, recent studies have shown that the adequacy of the initial antimicrobial therapy is not associated with a significant improvement of VAP prognosis, especially if a multidrug-resistant (MDR) Gram-negative bacterium is involved (Sommer et al. 2018; Titov et al. 2021). One likely explanation of the absence of benefit of adequate therapy within 24h is the rapid diffusion and expression of ARGs within the microbiome during treatment. It has been demonstrated the feasibility of characterizing lung microbiota by producing preliminary data from 174 respiratory samples collected in 65 patients included in the IBIS biobank within the IBIS cohort. These preliminary analyses have also confirmed that the respiratory microbiome of hospitalized patients shifts from a normal composition (day 1) to a specific pattern poor in Streptococcus and enriched in Haemophilus (day 7). Recently, it was observed in a randomized clinical trial that probiotics increase the ARG richness of the gut microbiome during antimicrobial treatment (Figure 2) (Montassier et al. 2021). These data demonstrated the ability to investigate the time course of ARG during treatment in human samples, and reinforce the hypothesis of rapid modifications of the ARG during treatment.
In summary, treatment failures are common in patients with CAP and HAP, even in cases of adequate antimicrobial therapy. Some specific antimicrobial therapies result in better outcomes than standard of cares and classical microbiology fail to explain this outcome.
Recent data demonstrated that the microbiome is a significant source of antibiotic resistance genes (ARG) which can rapidly be diffused between species during treatment.
In light of these preliminary results, we intend
- to define VAP and CAP sub-phenotypes based on the real-time course of the load of ARG in vivo
- to demonstrate in vivo that specific microbiome editing based on these phenotypes can enhance pneumonia outcomes.
The definition of these phenotypes of pneumonia is likely to impact the way patients are treated in daily practice, shifting the antimicrobial treatment from in vitro functional tests to in vivo prediction of response to treatment.
- Keywords
- Pneumonia, respiratory microbiome, antibiotic treatment
- Medical subject headings
- Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1 : community acquired pneumonia (CAP) hospitalized in the ward | Cohort 1 (CAP hospitalized in the ward) is a group with or without antibacterial exposure with few parameters interfering with the microbiota composition except for the present infection. | |
| Cohort 2 : CAP in intensive care unit (=ICU) | Cohort 2 (CAP in ICU) is a very severe subgroup always exposed to antibacterial agent during the pneumonia and other medications (or processes) interfering with microbiota composition during treatment. | |
| Cohort 3: acquiring hospital acquired pneumonia that needs invasive ventilation (=vHAP or VAP) | Cohort 3 (vHAP or VAP) is a very severe subgroup of patients exposed to broad spectrum antibacterial agents and other medications interfering with microbiota composition. Intubation required endotracheal aspirates during the current care and will allow comparison of the microbiota composition in the oropharynx and in the trachea. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms)
Clinical success is defined as :
- vHAP-VAP: resolution of the clinical symptoms that lead to the diagnosis on vHAP/VAP
Measured: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms)
Clinical success is defined as :
- CAP: resolution of fever and dyspnea, or oxygen therapy requirement clinical symptoms
Measured: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure
Microbiological failure is defined as:
- Persistence in standard culture of respiratory samples, of the microorganisms causing the pneumonia, independently from antibiotic susceptibility
Measured: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure
OR Microbiological failure is defined as:
Appearance, on respiratory sample, of a new pathogen considered as requiring a new antimicrobial therapy (superinfection) by the attending physician, before the test-of-cure visit (day 7-10).
Measured: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure or antibiotic resistance within the primary endpoint observation period, which will last 90 days after inclusion.
Antibiotic resistance is defined as one of the 3 following definitions:
- Detection of the same pneumonia pathogen but with resistance to at least one of the given antibiotics, on any respiratory sample collected after initial diagnosis;
Measured: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure or antibiotic resistance within the primary endpoint observation period, which will last 90 days after inclusion.
Antibiotic resistance is defined as one of the 3 following definitions:
- Occurrence of a new pathogen in respiratory specimens resistant to at least one of the given antibiotics;
Measured: 3 months
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure or antibiotic resistance within the primary endpoint observation period, which will last 90 days after inclusion.
Antibiotic resistance is defined as one of the 3 following definitions:
- Occurrence of a new pathogen in another site (infection, colonization or carriage) resistant the given antibiotic(s).
Measured: 3 months
Secondary outcomes (12)
Pneumonia relapse or recurrence
Pneumonia relapse or recurrence
Measured: 3 months
Time to clinical recovery (regardless of microbiological recovery or resistance failure)
To investigate the link between the composition of the respiratory microbiome at the start of treatment and pneumonia recurrence (second episode of pneumonia with at least one common pathogen)
Measured: 3 months
Time to clinical recovery (regardless of microbiological recovery or resistance failure)
To investigate the link between the composition of the respiratory microbiome at the start of treatment and pneumonia relapse (second episode of pneumonia with new pathogens)
Measured: 3 months
Presence or absence of antimicrobial resistance at any point during follow-up
To study the link between the composition of the respiratory microbiome at the start of treatment and the emergence of antibiotic resistance
Measured: 3 months
Association between specific antibiotics and respiratory microbiome evolution
To study the link between the antibiotic regimen (spectrum and dose) and time course of the respiratory microbiome composition and resistome
Measured: 3 months
Association between specific antibiotics and gut microbiome evolution
To study the link between the antibiotic regimen (spectrum and dose) and time course of the gut microbiome composition and resistome
Measured: 3 months
Duration of antimicrobial treatment
Duration of antimicrobial treatment
Measured: 3 months
Association between baseline microbiome and Acute Respiratory Distress Syndrome during pneumonia
To evaluate the link between the respiratory microbiome on baseline and Pneumonia severity (ARDS yes or no)
Measured: 3 months
Association between baseline microbiome and Length of initial hospital stay/ ICU stay
To evaluate the link between the respiratory microbiome on baseline and the length of hospital stay/ ICU stay after the start of antimicrobial treatment
Measured: 3 months
Association between baseline microbiome and All-cause mortality on day 28 and day 90
To evaluate the link between the respiratory microbiome on baseline and all-cause mortality on day 28 and day 90 after the start of antimicrobial treatment
Measured: 3 months
Quality of life questionnaires (EQ-5D-5L) on day 0, day 28 and day 90
To assess the quality of life on day 28 and day 90 after the start of antimicrobial therapy
Measured: 3 months
Correlation between oropharyngeal, endotracheal and gut microbiota profiles in intubated patients
To validate in intubated patients the relationship between oropharyngeal, endotracheal and gut microbiota profiles.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2025
- Study start6 Nov 2025
- Primary completion15 Sep 2027 (estimated)
- Study completion15 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Community Acquired or Acquiring Hospital Acquired PneumoniaStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06916481
- Sponsor's protocol ID
- APHP240040
- Other IDs
- 2024-A00116-41
- Acronym
- PHENOMENON
- Status last verified
- Apr 2025
- First submitted
- 1 Apr 2025
- Last updated
- 24 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Definition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures
- ClinicalTrials.gov ID
- NCT06916481
- Acronym / sponsor ID
- PHENOMENON / APHP240040
- Keywords
- Pneumonia, respiratory microbiome, antibiotic treatment
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 6 Nov 2025 (actual)
- Primary completion
- 15 Sep 2027 (estimated)
- Study completion
- 15 Sep 2028 (estimated)
- First posted
- 8 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Pneumonia remains a leading cause of antibiotic consumption globally, contributing significantly to the burden of antimicrobial resistance (AMR). The respiratory microbiome plays a crucial role in the emergence of AMR and therapeutic failure in both community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). The PHENOMENON study aims to investigate the relationship between the respiratory microbiome composition and clinical outcomes to improve the prediction of treatment failure and AMR emergence.
Methods: This multicenter prospective cohort study will include 300 adult patients across three cohorts: CAP in general wards, severe CAP in intensive care units (ICU), and ventilator-associated HAP (vHAP/VAP). Patients will undergo oropharyngeal and rectal swabbing at admission (Day 0), Day 3, Day 7-10, and Day 90, along with blood sampling and endotracheal aspirates in intubated patients. The primary objective is to assess the association between baseline respiratory microbiome composition and time to antibiotic response within 7-10 days. The composite primary endpoint includes clinical failure, microbiological failure, or AMR emergence. Secondary endpoints explore the association between microbiome composition and pneumonia recurrence, severity, hospital length of stay, and mortality at Day 28 and Day 90.
Expected Outcomes: This study will provide insights into the predictive value of respiratory microbiome composition on antibiotic response and AMR emergence. Understanding these relationships may guide personalized antibiotic strategies and optimize pneumonia management, ultimately reducing treatment failure rates and improving patient outcomes.
Detailed description
Pneumonia can be acquired in the community such as COVID-19 or flu, or during hospitalization for a different medical condition.
The significant burden of CAP is set to increase with ageing populations and growing rates of comorbidity. CAP was the leading cause of communicable diseases and the second cause of disability-adjusted life-years loss in the world in 2019, even before the COVID-19 pandemic (GBD 2019 Adolescent Mortality Collaborators 2021; GBD 2019 Diseases and Injuries Collaborators 2020). CAP is classically induced by virulent bacteria (such as Streptococcus pneumoniae) or viruses (influenza), but also new pathogenic viruses such as SARS-CoV-2 (COVID-19).
Incidence of VAP ranges from 5% to 67% depending on case mix and diagnostic criteria. In the US, the incidence of VAP ranges from 2 to 16 episodes per 1,000 ventilator-day. The estimated risk of VAP is initially high and decreases to less than 0.5% per day after 14 days of mechanical ventilation. VAP increases the duration of hospitalization by 7 days and health-care costs by approximately $40,000 USD per episode (Safdar et al. 2005; Eber et al. 2010). Antimicrobial resistance is rising, leading to increased durations of hospital stay and excess deaths in septic patients worldwide. The World Health Organization considers antibiotic resistance to be one of the biggest global health threats we are currently facing. AMR, including malaria, tuberculosis and bacterial infections, may increase to 10 million fatalities worldwide by 2050. While some resistance is intrinsic in some bacterial taxa, the main issue is acquired resistance, as bacteria can exchange genetic material and thereby spread antibiotic resistance genes (ARG).
Previous carriage of extended-spectrum beta-lactamases-producing Enterobacterales (ESBL-E) is found in 5 to 25% of ICU patients. Although a previous carriage is the major risk factor associated with VAP related to ESBL-E, only 5% to 20% of the ESBL-E carriers will develop a VAP related to ESBL-E. Carriage status therefore has a high negative predictive value for ESBL-E-associated VAP, whereas positive predictive value, i.e., the probability of having an ESBL-E infection in case of ESBL-E carriage, is less than 50%.
When caring for patients with VAP, recent studies have shown that the adequacy of the initial antimicrobial therapy is not associated with a significant improvement of VAP prognosis, especially if a multidrug-resistant (MDR) Gram-negative bacterium is involved (Sommer et al. 2018; Titov et al. 2021). One likely explanation of the absence of benefit of adequate therapy within 24h is the rapid diffusion and expression of ARGs within the microbiome during treatment. It has been demonstrated the feasibility of characterizing lung microbiota by producing preliminary data from 174 respiratory samples collected in 65 patients included in the IBIS biobank within the IBIS cohort. These preliminary analyses have also confirmed that the respiratory microbiome of hospitalized patients shifts from a normal composition (day 1) to a specific pattern poor in Streptococcus and enriched in Haemophilus (day 7). Recently, it was observed in a randomized clinical trial that probiotics increase the ARG richness of the gut microbiome during antimicrobial treatment (Figure 2) (Montassier et al. 2021). These data demonstrated the ability to investigate the time course of ARG during treatment in human samples, and reinforce the hypothesis of rapid modifications of the ARG during treatment.
In summary, treatment failures are common in patients with CAP and HAP, even in cases of adequate antimicrobial therapy. Some specific antimicrobial therapies result in better outcomes than standard of cares and classical microbiology fail to explain this outcome.
Recent data demonstrated that the microbiome is a significant source of antibiotic resistance genes (ARG) which can rapidly be diffused between species during treatment.
In light of these preliminary results, we intend
- to define VAP and CAP sub-phenotypes based on the real-time course of the load of ARG in vivo
- to demonstrate in vivo that specific microbiome editing based on these phenotypes can enhance pneumonia outcomes.
The definition of these phenotypes of pneumonia is likely to impact the way patients are treated in daily practice, shifting the antimicrobial treatment from in vitro functional tests to in vivo prediction of response to treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cohort 1 : community acquired pneumonia (CAP) hospitalized in the ward | – | –Cohort 1 (CAP hospitalized in the ward) is a group with or without antibacterial exposure with few parameters interfering with the microbiota composition except for the present infection. |
| Cohort 2 : CAP in intensive care unit (=ICU) | – | –Cohort 2 (CAP in ICU) is a very severe subgroup always exposed to antibacterial agent during the pneumonia and other medications (or processes) interfering with microbiota composition during treatment. |
| Cohort 3: acquiring hospital acquired pneumonia that needs invasive ventilation (=vHAP or VAP) | – | –Cohort 3 (vHAP or VAP) is a very severe subgroup of patients exposed to broad spectrum antibacterial agents and other medications interfering with microbiota composition. Intubation required endotracheal aspirates during the current care and will allow comparison of the microbiota composition in the oropharynx and in the trachea. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The population of interest is specific to each cohort. > For cohort 1: patients will be informed orally and in writing by the investigator on the delegation log during their hospitalization before inclusion. Patients will be informed of their right to decline participation and an informed written consent will be obtained by the investigator for biobank collection. > For cohorts 2 and 3: some patients may not be able to decline participation (sedated, ventilated). In these cases, relatives, if they are present, will be informed orally and in writing by the investigator on the delegation log. Relatives will be informed of their right to decline participation on behalf of the patient. Patients will be informed as soon as their health allows it. Patients will be informed of their right to decline to continue, and of their right to forbid the use of already collected data and/or samples.
Key inclusion criteria (20 listed)
- Cohort 1: CAP at emergency department and requiring hospitalization in general wards :
- Cohort 2: Severe CAP with ICU hospitalization :
- Cohort 3: vHAP or VAP :
Key exclusion criteria (26 listed)
- Cohort 1: CAP with hospitalization in general wards :
- Cohort 2: Severe CAP with ICU hospitalization :
- Cohort 3: vHAP or VAP :
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Time frame: 3 months
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) Clinical success is defined as : - vHAP-VAP: resolution of the clinical symptoms that lead to the diagnosis on vHAP/VAP
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Time frame: 3 months
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) Clinical success is defined as : - CAP: resolution of fever and dyspnea, or oxygen therapy requirement clinical symptoms
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Time frame: 3 months
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure Microbiological failure is defined as: - Persistence in standard culture of respiratory samples, of the microorganisms causing the pneumonia, independently from antibiotic susceptibility
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Time frame: 3 months
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure OR Microbiological failure is defined as: Appearance, on respiratory sample, of a new pathogen considered as requiring a new antimicrobial therapy (superinfection) by the attending physician, before the test-of-cure visit (day 7-10).
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Time frame: 3 months
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure or antibiotic resistance within the primary endpoint observation period, which will last 90 days after inclusion. Antibiotic resistance is defined as one of the 3 following definitions: - Detection of the same pneumonia pathogen but with resistance to at least one of the given antibiotics, on any respiratory sample collected after initial diagnosis;
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Time frame: 3 months
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure or antibiotic resistance within the primary endpoint observation period, which will last 90 days after inclusion. Antibiotic resistance is defined as one of the 3 following definitions: - Occurrence of a new pathogen in respiratory specimens resistant to at least one of the given antibiotics;
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment.
Time frame: 3 months
The measurement of interest for the primary endpoint will be the time to clinical success (resolution of symptoms) without subsequent microbiological failure or antibiotic resistance within the primary endpoint observation period, which will last 90 days after inclusion. Antibiotic resistance is defined as one of the 3 following definitions: - Occurrence of a new pathogen in another site (infection, colonization or carriage) resistant the given antibiotic(s).
12 secondary outcomes
Pneumonia relapse or recurrence
Time frame: 3 months
Time to clinical recovery (regardless of microbiological recovery or resistance failure)
Time frame: 3 months
Time to clinical recovery (regardless of microbiological recovery or resistance failure)
Time frame: 3 months
Presence or absence of antimicrobial resistance at any point during follow-up
Time frame: 3 months
Association between specific antibiotics and respiratory microbiome evolution
Time frame: 3 months
Association between specific antibiotics and gut microbiome evolution
Time frame: 3 months
Duration of antimicrobial treatment
Time frame: 3 months
Association between baseline microbiome and Acute Respiratory Distress Syndrome during pneumonia
Time frame: 3 months
Association between baseline microbiome and Length of initial hospital stay/ ICU stay
Time frame: 3 months
Association between baseline microbiome and All-cause mortality on day 28 and day 90
Time frame: 3 months
Quality of life questionnaires (EQ-5D-5L) on day 0, day 28 and day 90
Time frame: 3 months
Correlation between oropharyngeal, endotracheal and gut microbiota profiles in intubated patients
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Nov 2025.
Related trials for Community Acquired or Acquiring Hospital Acquired Pneumonia
Active, not recruitingObservational study
Prospective Hospital Registry of Patients With Suspected or Confirmed Coronavirus Infection (COVID-19) and Community-acquired Pneumonia
COVID 19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Community Acquired or Acquiring Hospital Acquired Pneumonia, run by Assistance Publique - Hôpitaux de Paris at 6 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jean-françois TIMSIT, MD, PHD (+ 33 1 40 25 77 07, jean-françois.timsit@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To study the relationship between the composition of the respiratory microbiome at the start of treatment and time to response to antibiotic treatment. (time frame: 3 months). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Nov 2025.